Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$10.40 – $11.48
Volume12,924
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PLRZ.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PLRZ.
Recent news
Company coverage with links to the original publishers.
Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The company specializes in developing intranasal protective solutions using proprietary hydrogel technology delivered as nasal sprays to create a barrier against viruses and allergens.
Polyrizon successfully completed a pre-submission meeting with the FDA regarding its PL-14 Allergy Blocker nasal spray, discussing development plans, manufacturing, and clinical trial strategies for a potential product targeting the growing global allergen blocker market.
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Polyrizon, a biotech company, has initiated preclinical studies for intranasal Naloxone, a treatment for opioid overdose, using its Trap and Target (T&T) platform. The studies aim to assess key parameters like drug loading, release kinetics, and nasal deposition, paving the way for further safety and efficacy testing.
Polyrizon, a biotech company, announced the filing of a divisional patent application for its Trap & Target (T&T) intranasal drug delivery platform. The T&T platform aims to enhance the effectiveness of medications by increasing their residence time and bioavailability.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.